BocaGreenMD, Inc. Launches Line of Generic Prescription Prenatal
BOCA RATON, Fla. -- November 01, 2012
TherapeuticsMD™, Inc. (OTCQB: TXMD), parent company of BocaGreenMD™, Inc.,
("BocaGreenMD") announced today that on November 6, 2012, BocaGreenMD will
launch its Prena1™ line of generic prescription prenatal vitamins designed to
meet the needs of pregnant mothers and women planning to become pregnant.
Prena1Plus is a comprehensive single dose dietary supplement containing one
prenatal tablet with 16 vitamins and minerals, plus one softgel with 300 mg of
Prena1 is a convenient, single daily softgel with 14 vitamins, minerals, and
200 mg of plant-based DHA.
Prena1 Chew is a single daily easy to chew, vanilla flavored, chewable tablet
ideal for women planning a pregnancy and those with difficulty swallowing
tablets or capsules, or where nausea or morning sickness makes taking tablets
or capsules difficult.
All Prena1 multivitamins contain a unique combination of folic acid and
Jason Spitz, Chief Marketing Officer of BocaGreenMD, stated, "We are very
excited to introduce our Prena1 prenatal multivitamins with a unique
combination of folic acid and plant-based DHA. Prena1 prenatal multivitamins
will be welcomed by health care providers and pharmacists as innovative
generic products that offer patients and customers a cost-effective choice
without sacrificing quality. Prena1, Prena1 Plus, and Prena1 Chew are
available by prescription only at chain, independent, and mail order
pharmacies throughout the United States."
BocaGreenMD is a pharmaceutical company that focuses on developing authorized
generics for women’s health products. Creating value and savings for the
consumer without sacrificing quality will drive innovation at BocaGreenMD.
Questions may be directed to Daniel A. Cartwright, BocaGreenMD's Chief
Financial Officer, at (561) 961-1911. More information on BocaGreenMD and its
products are available at www.bocagreenmd.com or www.prena1.com.
TherapeuticsMD, Inc.is a specialty pharmaceutical company focused on creating
safe and effective therapies exclusively for women. The Company’s branded
over-the-counter ("OTC") and pharmaceutical products are designed to improve
the health and well-being of women from pregnancy through menopause. Questions
may be directed to Daniel A. Cartwright, the Company's Chief Financial
Officer, at (561) 961-1911. Additional information on TherapeuticsMD is
available on its website at www.therapeuticsmd.com.
This press release shall not constitute an offer to sell or a solicitation of
an offer to buy securities of TherapeuticsMD, Inc., nor shall there be any
sale of these securities in any state in which such offer, solicitation, or
sale would be unlawful. Certain statements in this release and other written
or oral statements made by or on behalf of the Company are “forward-looking
statements” within the meaning of the federal securities laws. Statements
regarding future events and developments and our future performance, including
the Company’s receipt of gross proceeds from the private placement, intended
use of such proceeds, and plans to begin Phase III trials and launch three
generic prescription prenatal vitamin products, as well as management’s
expectations, beliefs, plans, estimates, or projections relating to the future
are forward-looking statements within the meaning of these laws. The
forward-looking statements are subject to a number of risks and uncertainties
including FDA and market acceptance of the Company’s products and the
Company’s continued access to capital and other risks and uncertainties
identified in the Company’s Form 10-K and other filings with the Securities
and Exchange Commission.. The actual results the Company achieves may differ
materially from any forward-looking statements due to such risks and
uncertainties. These statements are based on our current expectations and
speak only as of the date of such statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statement, whether
as a result of future events, new information, or otherwise.
Daniel A. Cartwright, 561-961-1911
Press spacebar to pause and continue. Press esc to stop.